Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 18:13:840956.
doi: 10.3389/fimmu.2022.840956. eCollection 2022.

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021

Lele Miao  1   2 , Juan Zhang  3 , Zhengchao Zhang  1   2 , Song Wang  1   2 , Futian Tang  2 , Muzhou Teng  2   4 , Yumin Li  1   2   4
Affiliations

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021

Lele Miao et al. Front Immunol. .

Abstract

Objectives: A bibliometric and knowledge-map analysis is used to explore hotspots' evolution and development trends in the CAR-T cell field. By looking for research hotspots and new topics, we can provide new clues and ideas for researchers in this field.

Methods: The articles and reviews regarding CAR-T cells were retrieved and obtained from the Web of Science Core Collection (WOSCC) on October 28th, 2021. CtieSpace [version 5.8.R3 (64-bit)] and VOSviewer (version 1.6.17) were used to conduct the bibliometric and knowledge-map analysis.

Results: 660 authors from 488 institutions in 104 countries/regions published 6,867 papers in 1,212 academic journals. The United States was absolutely in the leading position in this research field. The institution that contributed the most publications was the University of Pennsylvania. Carl H June published the most articles, while Shannon L Maude had the most co-citations. However, there was little cooperation between countries. After 2012, cooperation among various institutions was also small. The journals that published the most CAR-T cell-related papers were Frontiers in immunology and Cancers. Nevertheless, Blood and The New England Journal of Medicine were the most commonly co-cited journals. The most influential research hotspots were the research of CAR-T cells in hematological malignancies, the related research of cytokine release syndrome (CRS), CD19, and the anti-tumor activity and efficacy of CAR-T cells. The latest hotspots and topics included the study of CAR-T cells in solid tumors, universal CAR-T cells, CAR-NK cells, CD22, and anakinra (the IL-1 receptor antagonist). The research of CAR-T cells in solid tumors was a rapidly developing hot field. Emerging topics in this field mainly included the study of CAR-T cells in glioblastoma (related targets: IL13Rα2, EGFRvIII, and HER2), neuroblastoma (related target: GD2), sarcoma (related target: HER2), and pancreatic cancer (related target: mesothelin), especially glioblastoma.

Conclusion: As an anti-tumor therapy with great potential and clinical application prospects, CAR-T cell therapy is still in a stage of rapid development. The related field of CAR-T cells will remain a research hotspot in the future.

Keywords: CAR-T cell; Citespace; VOSviewer; bibliometric; hotspots; knowledge-map; topics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The trend of publication outputs about CAR-T cells.
Figure 2
Figure 2
The co-occurrence map of countries/regions (A) and institutions (B) in CAR-T cell research.
Figure 3
Figure 3
The density map of journals (A) and co-cited journals (B) in CAR-T cell research. (A) shows journals with several publications ≥10; (B) shows the journals with citations ≥200.
Figure 4
Figure 4
The dual-map overlay of journals on CAR-T cells. Image parameter: a: 2; Source Circle Size: 25; Target Circle Size: 3; Snap to centroids (< Radius): 0. The citing journals are located on the left, and the cited journals are located on the right. The color paths (two orange and two green reference paths) represent the cited relationship.
Figure 5
Figure 5
CiteSpace visualization map of authors involved in CAR-T cells.
Figure 6
Figure 6
CiteSpace visualization map of co-cited authors involved in CAR-T cells.
Figure 7
Figure 7
The co-occurrence density map of keywords related to CAR-T cell research. Minimum number of occurrences of keywords ≥20.
Figure 8
Figure 8
The co-occurrence network and clusters of keywords related to CAR-T cell research. Minimum number of occurrences of keywords ≥20.
Figure 9
Figure 9
CiteSpace visualization map of timeline viewer related to CAR-T cells.
Figure 10
Figure 10
The top 50 references with the strongest citation bursts involved in CAR-T cells. The Blue bars mean the reference had been published; the red bars mean citation burstness.
See this image and copyright information in PMC

References

    1. Hong M, Clubb JD, Chen YY. Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell (2020) 38(4):473–88. doi: 10.1016/j.ccell.2020.07.005 - DOI - PubMed
    1. Liang Z, Dong J, Yang N, Li SD, Yang ZY, Huang R, et al. . Tandem CAR-T Cells Targeting FOLR1 and MSLN Enhance the Anti-Tumor Effects in Ovarian Cancer. Int J Biol Sci (2021) 17(15):4365–76. doi: 10.7150/ijbs.63181 - DOI - PMC - PubMed
    1. Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, et al. . A Novel and Efficient Tandem CD19- and CD22-Directed CAR for B Cell ALL. Mol Ther: J Am Soc Gene Ther (2021) 30(2):550–63. doi: 10.1016/j.ymthe.2021.08.033 - DOI - PMC - PubMed
    1. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. . Tandem CAR T Cells Targeting HER2 and IL13Rα2 Mitigate Tumor Antigen Escape. J Clin Invest (2021) 131(13):e152477. doi: 10.1172/jci152477 - DOI - PMC - PubMed
    1. Zhang Y, Wang Y, Liu Y, Tong C, Wang C, Guo Y, et al. . Long-Term Activity of Tandem CD19/CD20 CAR Therapy in Refractory/Relapsed B-Cell Lymphoma: A Single-Arm, Phase 1-2 Trial. Leukemia (2021) 36(1):189–96. doi: 10.1038/s41375-021-01345-8 - DOI - PMC - PubMed

Publication types